VSTM250117P10000
- 0.00
- 0.000.00%
Verastem Newsroom
Citi Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $7
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $7
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
Verastem Is Maintained at Outperform by Mizuho
Verastem Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Verastem Analyst Ratings
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Announces Target Price $9
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
Verastem's Promising Drug Combination for LGSOC: Analyst Recommends Buy Rating
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Strategic Advancements and Market Opportunities Propel Verastem's Buy Rating
Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15
Verastem (VSTM) Receives a Buy From RBC Capital
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15
Verastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial Potential